Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GW 572016

Known as: GW-572016, GW572016 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Background: Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Highly Cited
2008
Highly Cited
2008
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2008
Highly Cited
2008
Lapatinib [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Highly Cited
2006
Highly Cited
2006
Lapatinib (GW572016) is a selective inhibitor of both epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. Here… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2005
Highly Cited
2005
PURPOSE This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
2005
Highly Cited
2005
PURPOSE This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients… Expand
Highly Cited
2005
Highly Cited
2005
Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of… Expand
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2005
Highly Cited
2005
Effective treatment of estrogen receptor (ER)-positive breast cancers with tamoxifen is often curtailed by the development of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2004
Highly Cited
2004
GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2002
Highly Cited
2002
Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5